Milestone Pharmaceuticals Inc. Files 8-K
Ticker: MIST · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1408443
Sentiment: neutral
Topics: material-definitive-agreement, filing, pharmaceuticals
TL;DR
Milestone Pharma signed a big deal on Feb 28th, filing an 8-K.
AI Summary
On February 28, 2024, Milestone Pharmaceuticals Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also reported other events and filed financial statements and exhibits. Milestone Pharmaceuticals Inc. is incorporated in Quebec and its principal executive offices are located in Montreal.
Why It Matters
This 8-K filing indicates a significant event for Milestone Pharmaceuticals Inc., likely related to a new agreement that could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant opportunities or risks depending on the undisclosed terms.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- February 28, 2024 (date) — Date of earliest event reported
- Quebec (location) — State of incorporation
- Montreal (location) — City of principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Milestone Pharmaceuticals Inc. on February 28, 2024?
The filing states that Milestone Pharmaceuticals Inc. entered into a material definitive agreement on February 28, 2024, but the specific details of this agreement are not provided in the text.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 28, 2024.
Where are the principal executive offices of Milestone Pharmaceuticals Inc. located?
The principal executive offices of Milestone Pharmaceuticals Inc. are located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, H4M 2X6.
In which jurisdiction is Milestone Pharmaceuticals Inc. incorporated?
Milestone Pharmaceuticals Inc. is incorporated in Québec.
What is the SIC code for Milestone Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Milestone Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,383 words · 6 min read · ~5 pages · Grade level 11.5 · Accepted 2024-03-04 09:00:21
Key Financial Figures
- $1.50 — Shares"), at a public offering price of $1.50 per share and, in lieu of Common Shares
- $1.499 — arrants") at a public offering price of $1.499 per Pre-Funded Warrant, which represent
- $0.001 — ng price for the Common Shares less the $0.001 per share exercise price for each such
- $32.4 million — full, are expected to be approximately $32.4 million after deducting underwriting commission
Filing Documents
- tm247820d1_8k.htm (8-K) — 39KB
- tm247820d1_ex1-1.htm (EX-1.1) — 244KB
- tm247820d1_ex4-1.htm (EX-4.1) — 63KB
- tm247820d1_ex5-1.htm (EX-5.1) — 12KB
- tm247820d1_ex5-2.htm (EX-5.2) — 13KB
- tm247820d1_ex99-1.htm (EX-99.1) — 11KB
- tm247820d1_ex99-2.htm (EX-99.2) — 11KB
- tm247820d1_ex99-2img01.jpg (GRAPHIC) — 4KB
- tm247820d1_ex99-2img02.jpg (GRAPHIC) — 4KB
- tm247820d_ex5-1img01.jpg (GRAPHIC) — 3KB
- tm247820d_ex5-2img002.jpg (GRAPHIC) — 3KB
- 0001104659-24-030267.txt ( ) — 688KB
- mist-20240228.xsd (EX-101.SCH) — 3KB
- mist-20240228_lab.xml (EX-101.LAB) — 33KB
- mist-20240228_pre.xml (EX-101.PRE) — 22KB
- tm247820d1_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 1.1 Underwriting Agreement, dated February 28, 2024, by and between the Company and Piper Sandler & Co. 4.1 Form of Pre-Funded Warrant 5.1 Opinion of Osler, Hoskin & Harcourt LLP 5.2 Opinion of Cooley LLP 23.1 Consent of Osler, Hoskin & Harcourt LLP (included in Exhibit 5.1) 23.2 Consent of Cooley LLP (included in Exhibit 5.2) 99.1 Press Release, dated February 28, 2024 99.2 Press Release, dated February 29, 2024 104 Cover Page Interactive Data File (embedded with Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MILESTONE PHARMACEUTICALS INC. Date: March 4, 2024 By: /s/ Amit Hasija Amit Hasija Chief Financial Officer Principal Financial Officer